+
CCI clears Torrent Pharma’s acquisition of JB Chemicals
ECONOMY & POLICY

CCI clears Torrent Pharma’s acquisition of JB Chemicals

The Competition Commission of India (CCI) has approved the proposed acquisition of J. B. Chemicals & Pharmaceuticals Limited by Torrent Pharmaceuticals Limited, subject to voluntary modifications offered by the parties.

The transaction involves Torrent Pharmaceuticals Limited (the acquirer) purchasing shareholding in J. B. Chemicals & Pharmaceuticals Limited (the target), followed by the amalgamation of the target company with the acquirer. Together, the two entities are referred to as the “parties”.

Torrent Pharmaceuticals, the flagship company of the Torrent Group, is engaged in the manufacture and sale of pharmaceutical formulations across multiple therapeutic segments.

J. B. Chemicals & Pharmaceuticals Limited operates in the manufacturing and marketing of a wide range of finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs). The company also provides Contract Development and Manufacturing Organisation (CDMO) services.

The CCI’s approval is conditional on the compliance of voluntary modifications proposed by both parties to address competition concerns.

A detailed order from the Commission will be issued in due course.

The Competition Commission of India (CCI) has approved the proposed acquisition of J. B. Chemicals & Pharmaceuticals Limited by Torrent Pharmaceuticals Limited, subject to voluntary modifications offered by the parties. The transaction involves Torrent Pharmaceuticals Limited (the acquirer) purchasing shareholding in J. B. Chemicals & Pharmaceuticals Limited (the target), followed by the amalgamation of the target company with the acquirer. Together, the two entities are referred to as the “parties”. Torrent Pharmaceuticals, the flagship company of the Torrent Group, is engaged in the manufacture and sale of pharmaceutical formulations across multiple therapeutic segments. J. B. Chemicals & Pharmaceuticals Limited operates in the manufacturing and marketing of a wide range of finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs). The company also provides Contract Development and Manufacturing Organisation (CDMO) services. The CCI’s approval is conditional on the compliance of voluntary modifications proposed by both parties to address competition concerns. A detailed order from the Commission will be issued in due course.

Next Story
Infrastructure Transport

Lucknow Metro East-West Corridor Consultancy Contract Awarded

The Uttar Pradesh Metro Rail Corporation has awarded the first construction-related consultancy contract for the Lucknow Metro East West Corridor to a joint venture of AYESA Ingenieria Arquitectura SAU and AYESA India Pvt Ltd. The firm was declared the lowest bidder for the Detailed Design Consultant contract for Lucknow Metro Line-2 under Phase 1B and the contract was recommended following the financial bid. The contract is valued at Rs 159.0 million (mn), covering design services for the corridor. Lucknow Metro Line-2 envisages the construction of an 11.165 kilometre corridor connecting Cha..

Next Story
Infrastructure Urban

Div Com Kashmir Urges Fast Tracking Of Jhelum Water Transport Project

The Divisional Commissioner of Kashmir has called for the fast-tracking of the Jhelum water transport project, urging district administrations and relevant agencies to accelerate planning and clearances. In a meeting convened at the divisional headquarters, the commissioner instructed officials from irrigation, public health engineering and municipal departments to prioritise the project and coordinate survey and design work. The directive emphasised removal of administrative bottlenecks and close monitoring to ensure timely mobilisation of resources and contractors. Officials were told to in..

Next Story
Infrastructure Urban

Interarch Reports Strong Q3 And Nine Month Results

Interarch Building Solutions Limited reported unaudited results for the third quarter and nine months ended 31 December 2025, recording strong revenue growth driven by execution and a robust order book. Net revenue for the third quarter rose by 43.7 per cent to Rs 5.225 billion (bn), compared with Rs 3.636 bn a year earlier, reflecting heightened demand in pre-engineered building projects. The company’s total order book as at 31 January 2026 stood at Rs 16.85 bn, supporting near-term visibility. EBITDA excluding other income for the quarter increased by 43.2 per cent to Rs 503 million (mn),..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Open In App